<p>ANI 制药公司（NASDAQ:ANIP - 获取免费报告）的股票在周一的午盘交易中因内部人士出售活动下跌了 3.6%。该股最低交易价格为 79.36 美元，最后交易价格为 79.8450 美元。在交易中大约有 86,438 股成交，较平均每日成交量 377,608 股下降了 77%。该股此前收盘价为 82.85 美元。</p>
<p>获取 <strong>ANI 制药</strong> 的提醒：</p>
<p>具体来说，高级副总裁 Krista Davis 在 12 月 18 日星期四出售了 1,622 股公司的股票，交易的平均价格为 82.40 美元，总交易额为 133,652.80 美元。交易完成后，这位高级副总裁直接持有公司 58,564 股，价值 4,825,673.60 美元。此次交易使其持股比例减少了 2.69%。该出售在向证券交易委员会提交的文件中披露，文件可通过此链接获取。</p>
<h2>分析师评级变动</h2>
<p>ANI 制药已成为多份研究分析师报告的主题。Guggenheim 在 11 月 10 日的报告中将 ANI 制药的目标价格从 114.00 美元上调至 115.00 美元，并给予该公司 “买入” 评级。HC Wainwright 在 9 月 17 日的研究报告中将 ANI 制药的目标价格从 93.00 美元上调至 121.00 美元，并给予该股 “买入” 评级。巴克莱在 12 月 9 日的研究报告中开始覆盖 ANI 制药，给予 “增持” 评级和 100.00 美元的目标价格。Truist Financial 在 10 月 9 日的研究报告中将 ANI 制药的目标价格从 77.00 美元上调至 90.00 美元，并给予该公司 “持有” 评级。最后，Weiss Ratings 在 12 月 15 日的报告中将 ANI 制药的评级从 “买入（b-）” 下调至 “持有（c+）”。一位研究分析师给予该股 “强烈买入” 评级，六位分析师给予 “买入” 评级，两位分析师给予 “持有” 评级。根据 MarketBeat 的数据，ANI 制药的平均评级为 “适度买入”，平均目标价格为 102.14 美元。</p>
<p><strong>查看我们对 ANI 制药的最新分析</strong></p>
<h2>ANI 制药股票下跌 3.6%</h2>
<p>该股市值为 17.9 亿美元，市盈率为 49.04，贝塔值为 0.48。公司流动比率为 2.04，当前比率为 2.58，债务股本比率为 1.20。该股的 50 日移动平均价格为 86.70 美元，200 日移动平均价格为 81.62 美元。</p>
<p>ANI 制药（NASDAQ:ANIP - 获取免费报告）最近在 11 月 7 日发布了季度财报。这家专业制药公司报告每股收益（EPS）为 2.04 美元，超出分析师一致预期的 1.74 美元，超出幅度为 0.30 美元。ANI 制药的净利润率为 4.91%，股本回报率为 26.73%。该公司在本季度的收入为 2.2781 亿美元，而分析师预期为 2.1192 亿美元。去年同期，该公司每股收益为 1.34 美元。该公司的季度收入同比增长 53.6%。ANI 制药已将 2025 财年的指导目标设定为每股收益 7.370-7.640 美元。整体来看，分析师预测 ANI 制药将在当前年度发布每股收益 3.86 美元。</p>
<h2>ANI 制药的机构交易</h2>
<p>几家机构投资者最近调整了对该公司的持股。Intech Investment Management LLC 在第二季度将其在 ANI 制药的持股增加了 134.7%。Intech Investment Management LLC 目前持有 26,917 股该专业制药公司的股票，价值 1,756,000 美元，此前在上个季度购买了 15,447 股。Envestnet Asset Management Inc.在第二季度将其在 ANI 制药的持股增加了 59.9%。Envestnet Asset Management Inc.目前持有 10,326 股该专业制药公司的股票，价值 674,000 美元，此前在上个季度购买了 3,869 股。Squarepoint Ops LLC 在第二季度获得了 ANI 制药的新头寸，价值 2,137,000 美元。Dynamic Technology Lab Private Ltd 在第二季度获得了 ANI 制药的新头寸，价值 209,000 美元。最后，Sio Capital Management LLC 在第二季度将其在 ANI 制药的持股增加了 29.4%。Sio Capital Management LLC 目前持有 112,923 股该专业制药公司的股票，价值 7,368,000 美元，此前在上个季度购买了 25,625 股。机构投资者持有该公司 76.05% 的股票。</p>
<h2>ANI 制药公司简介</h2>
<p>（获取免费报告）</p>
<p>ANI 制药公司是一家总部位于美国的专业制药公司，专注于仿制药和品牌处方药的开发、生产和商业化。该公司作为一个端到端的提供商，提供从活性药物成分（API）生产和配方开发到成品剂型制造和包装的服务。</p>
<p>ANI 的产品组合涵盖了多个治疗领域的注射和口服疗法，包括内分泌学、肿瘤学、疼痛管理和呼吸护理。</p>
<h2>特色故事</h2>
<ul>
<li>五只我们更看好的股票超过 ANI 制药</li>
<li>美联储转向信号，聪明资金一直在等待</li>
<li>这家 AI-量子公司预计 2025 年收入将达到 2.74 亿美元</li>
<li>华尔街股票挑选者命名 2026 年第一只股票</li>
<li>请勿删除，立即阅读</li>
<li>“客户银行存款 660 亿美元面临风险”</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 ANI 制药吗？</h2>
<p>在考虑 ANI Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 ANI Pharmaceuticals 并不在名单上。</p>
<p>虽然 ANI Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

ANI制药

<p>ANI 制药（NASDAQ:ANIP）的股票因高级副总裁 Krista Davis 出售 1,622 股而下跌 3.6%。该股票交易低点为 79.36 美元，交易量显著下降。尽管出现下滑，分析师仍维持 “适度买入” 评级，平均目标价为 102.14 美元。该公司报告了强劲的季度收益，超出预期，市值为 17.9 亿美元</p>

<p>Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) were down 3.6% during mid-day trading on Monday following insider selling activity. The stock traded as low as $79.36 and last traded at $79.8450. Approximately 86,438 shares traded hands during trading, a decline of 77% from the average daily volume of 377,608 shares. The stock had previously closed at $82.85.</p>
<div class="lb-trans"><p>ANI 制药公司（NASDAQ:ANIP - 获取免费报告）的股票在周一的午盘交易中因内部人士出售活动下跌了 3.6%。该股最低交易价格为 79.36 美元，最后交易价格为 79.8450 美元。在交易中大约有 86,438 股成交，较平均每日成交量 377,608 股下降了 77%。该股此前收盘价为 82.85 美元。</p>
</div><p>Get <strong>ANI Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>ANI 制药</strong> 的提醒：</p>
</div><p>Specifically, SVP Krista Davis sold 1,622 shares of the business's stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $82.40, for a total transaction of $133,652.80. Following the completion of the transaction, the senior vice president directly owned 58,564 shares in the company, valued at $4,825,673.60. The trade was a 2.69% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this link.</p>
<div class="lb-trans"><p>具体来说，高级副总裁 Krista Davis 在 12 月 18 日星期四出售了 1,622 股公司的股票，交易的平均价格为 82.40 美元，总交易额为 133,652.80 美元。交易完成后，这位高级副总裁直接持有公司 58,564 股，价值 4,825,673.60 美元。此次交易使其持股比例减少了 2.69%。该出售在向证券交易委员会提交的文件中披露，文件可通过此链接获取。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>ANIP has been the topic of a number of research analyst reports. Guggenheim raised their target price on ANI Pharmaceuticals from $114.00 to $115.00 and gave the company a &#34;buy&#34; rating in a report on Monday, November 10th. HC Wainwright upped their price objective on ANI Pharmaceuticals from $93.00 to $121.00 and gave the stock a &#34;buy&#34; rating in a research report on Wednesday, September 17th. Barclays initiated coverage on ANI Pharmaceuticals in a research note on Tuesday, December 9th. They issued an &#34;overweight&#34; rating and a $100.00 price objective on the stock. Truist Financial lifted their target price on ANI Pharmaceuticals from $77.00 to $90.00 and gave the company a &#34;hold&#34; rating in a research report on Thursday, October 9th. Finally, Weiss Ratings cut shares of ANI Pharmaceuticals from a &#34;buy (b-)&#34; rating to a &#34;hold (c+)&#34; rating in a report on Monday, December 15th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, ANI Pharmaceuticals has an average rating of &#34;Moderate Buy&#34; and an average price target of $102.14.</p>
<div class="lb-trans"><p>ANI 制药已成为多份研究分析师报告的主题。Guggenheim 在 11 月 10 日的报告中将 ANI 制药的目标价格从 114.00 美元上调至 115.00 美元，并给予该公司 “买入” 评级。HC Wainwright 在 9 月 17 日的研究报告中将 ANI 制药的目标价格从 93.00 美元上调至 121.00 美元，并给予该股 “买入” 评级。巴克莱在 12 月 9 日的研究报告中开始覆盖 ANI 制药，给予 “增持” 评级和 100.00 美元的目标价格。Truist Financial 在 10 月 9 日的研究报告中将 ANI 制药的目标价格从 77.00 美元上调至 90.00 美元，并给予该公司 “持有” 评级。最后，Weiss Ratings 在 12 月 15 日的报告中将 ANI 制药的评级从 “买入（b-）” 下调至 “持有（c+）”。一位研究分析师给予该股 “强烈买入” 评级，六位分析师给予 “买入” 评级，两位分析师给予 “持有” 评级。根据 MarketBeat 的数据，ANI 制药的平均评级为 “适度买入”，平均目标价格为 102.14 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on ANI Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我们对 ANI 制药的最新分析</strong></p>
</div><h2>ANI Pharmaceuticals Stock Down 3.6%</h2>
<div class="lb-trans"><h2>ANI 制药股票下跌 3.6%</h2>
</div><p>The stock has a market capitalization of $1.79 billion, a price-to-earnings ratio of 49.04 and a beta of 0.48. The company has a quick ratio of 2.04, a current ratio of 2.58 and a debt-to-equity ratio of 1.20. The stock has a 50 day moving average price of $86.70 and a 200 day moving average price of $81.62.</p>
<div class="lb-trans"><p>该股市值为 17.9 亿美元，市盈率为 49.04，贝塔值为 0.48。公司流动比率为 2.04，当前比率为 2.58，债务股本比率为 1.20。该股的 50 日移动平均价格为 86.70 美元，200 日移动平均价格为 81.62 美元。</p>
</div><p>ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last issued its quarterly earnings data on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.74 by $0.30. ANI Pharmaceuticals had a net margin of 4.91% and a return on equity of 26.73%. The business had revenue of $227.81 million during the quarter, compared to analyst estimates of $211.92 million. During the same quarter last year, the business earned $1.34 EPS. The firm's quarterly revenue was up 53.6% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. As a group, analysts forecast that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current year.</p>
<div class="lb-trans"><p>ANI 制药（NASDAQ:ANIP - 获取免费报告）最近在 11 月 7 日发布了季度财报。这家专业制药公司报告每股收益（EPS）为 2.04 美元，超出分析师一致预期的 1.74 美元，超出幅度为 0.30 美元。ANI 制药的净利润率为 4.91%，股本回报率为 26.73%。该公司在本季度的收入为 2.2781 亿美元，而分析师预期为 2.1192 亿美元。去年同期，该公司每股收益为 1.34 美元。该公司的季度收入同比增长 53.6%。ANI 制药已将 2025 财年的指导目标设定为每股收益 7.370-7.640 美元。整体来看，分析师预测 ANI 制药将在当前年度发布每股收益 3.86 美元。</p>
</div><h2>Institutional Trading of ANI Pharmaceuticals</h2>
<div class="lb-trans"><h2>ANI 制药的机构交易</h2>
</div><p>Several institutional investors have recently modified their holdings of the business. Intech Investment Management LLC lifted its holdings in shares of ANI Pharmaceuticals by 134.7% in the 2nd quarter. Intech Investment Management LLC now owns 26,917 shares of the specialty pharmaceutical company's stock worth $1,756,000 after purchasing an additional 15,447 shares in the last quarter. Envestnet Asset Management Inc. increased its stake in ANI Pharmaceuticals by 59.9% during the 2nd quarter. Envestnet Asset Management Inc. now owns 10,326 shares of the specialty pharmaceutical company's stock valued at $674,000 after purchasing an additional 3,869 shares in the last quarter. Squarepoint Ops LLC acquired a new position in ANI Pharmaceuticals during the second quarter worth $2,137,000. Dynamic Technology Lab Private Ltd acquired a new position in ANI Pharmaceuticals during the second quarter worth $209,000. Finally, Sio Capital Management LLC lifted its stake in shares of ANI Pharmaceuticals by 29.4% in the second quarter. Sio Capital Management LLC now owns 112,923 shares of the specialty pharmaceutical company's stock valued at $7,368,000 after buying an additional 25,625 shares in the last quarter. Institutional investors own 76.05% of the company's stock.</p>
<div class="lb-trans"><p>几家机构投资者最近调整了对该公司的持股。Intech Investment Management LLC 在第二季度将其在 ANI 制药的持股增加了 134.7%。Intech Investment Management LLC 目前持有 26,917 股该专业制药公司的股票，价值 1,756,000 美元，此前在上个季度购买了 15,447 股。Envestnet Asset Management Inc.在第二季度将其在 ANI 制药的持股增加了 59.9%。Envestnet Asset Management Inc.目前持有 10,326 股该专业制药公司的股票，价值 674,000 美元，此前在上个季度购买了 3,869 股。Squarepoint Ops LLC 在第二季度获得了 ANI 制药的新头寸，价值 2,137,000 美元。Dynamic Technology Lab Private Ltd 在第二季度获得了 ANI 制药的新头寸，价值 209,000 美元。最后，Sio Capital Management LLC 在第二季度将其在 ANI 制药的持股增加了 29.4%。Sio Capital Management LLC 目前持有 112,923 股该专业制药公司的股票，价值 7,368,000 美元，此前在上个季度购买了 25,625 股。机构投资者持有该公司 76.05% 的股票。</p>
</div><h2>ANI Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>ANI 制药公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.</p>
<div class="lb-trans"><p>ANI 制药公司是一家总部位于美国的专业制药公司，专注于仿制药和品牌处方药的开发、生产和商业化。该公司作为一个端到端的提供商，提供从活性药物成分（API）生产和配方开发到成品剂型制造和包装的服务。</p>
</div><p>ANI's product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.</p>
<div class="lb-trans"><p>ANI 的产品组合涵盖了多个治疗领域的注射和口服疗法，包括内分泌学、肿瘤学、疼痛管理和呼吸护理。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>特色故事</h2>
</div><ul>
<li>Five stocks we like better than ANI Pharmaceuticals</li>
<li>The Fed Pivot Signal Smart Money’s Been Waiting For</li>
<li>This AI–Quantum Company Expects to Hit $274M in Revenue for 2025</li>
<li>Wall Street Stock picker Names #1 Stock of 2026</li>
<li>Do not delete, read immediately</li>
<li>“$6.6 Trillion Of Customer Bank Deposits At Risk”</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 ANI 制药</li>
<li>美联储转向信号，聪明资金一直在等待</li>
<li>这家 AI-量子公司预计 2025 年收入将达到 2.74 亿美元</li>
<li>华尔街股票挑选者命名 2026 年第一只股票</li>
<li>请勿删除，立即阅读</li>
<li>“客户银行存款 660 亿美元面临风险”</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in ANI Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 ANI 制药吗？</h2>
</div><p>Before you consider ANI Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 ANI Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ANI Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 ANI Pharmaceuticals 并不在名单上。</p>
</div><p>While ANI Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 ANI Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

ANI 制药（NASDAQ:ANIP）因内部人士出售股票导致股价下跌 3.6%